About Sungen

On December 21, 2018, Sungen Biomedical was established in Beijing, China. Professor Sun Zhiwei's research team started the development of antibody drugs of innovative targets.

In November 2022, Sungen Biomedical obtained the qualification of Zhongguancun High-tech Enterprise;

On October 31, 2023, Shenzhen Zhiyuan Biomedical Co., LTD. and Beijing Sungen Biomedical Technology Co., LTD. set up the "National Human Brain Health project" joint laboratory.

In February 2024, SGC001 project completed CMC study and non-clinical safety evaluation, and submitted the pre-IND application in China and the United States.

On August 05, 2024, Sungen Biomedical SGC001 injection obtained the clinical trial implied approval from Center for Drug Evaluation, National Medical Products Administration.

On November 19, 2024, Sungen Biomedical won the first prize of Beijing Science and Technology Progress Award 2023

In 2024, the clinical trial application (IND) for SGC001, the world’s first-in-class innovative drug developed by Beijing Sungen Biomedical Technology Co., Ltd., received approval from the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA).